grin1-protein

NMDA Receptor Subunit 1 Protein (GluN1)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">grin1-protein</th>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">PSD-95</td>
<td>PDZ binding</td>
</tr>
<tr>
<td class="label">SAP-97</td>
<td>PDZ binding</td>
</tr>
<tr>
<td class="label">Homer</td>
<td>PDZ binding</td>
</tr>
<tr>
<td class="label">CaMKII</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">PKA</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">PKC</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">Src-family kinases</td>
<td>Tyrosine phosphorylation</td>
</tr>
<tr>
<td class="label">GRIP1</td>
<td>PDZ binding</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Memantine</td>
<td>Uncompetitive NMDA antagonist</td>
</tr>
<tr>
<td class="label">Ketamine</td>
<td>Non-competitive antagonist</td>
</tr>
<tr>
<td class="label">D-cycloserine</td>
<td>Partial agonist at glycine site</td>
</tr>
<tr>
<td class="label">Site</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">Ser896 (GluN1)</td>
<td>PKC</td>
</tr>
<tr>
<td class="label">Ser897 (GluN1)</td>
<td>PKC</td>
</tr>
<tr>
<td class="label">Tyr1325 (GluN2B)</td>
<td>Src</td>
</tr>
<tr>
<td class="label">Tyr1472 (GluN2B)</t

NMDA Receptor Subunit 1 Protein (GluN1)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">grin1-protein</th>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">PSD-95</td>
<td>PDZ binding</td>
</tr>
<tr>
<td class="label">SAP-97</td>
<td>PDZ binding</td>
</tr>
<tr>
<td class="label">Homer</td>
<td>PDZ binding</td>
</tr>
<tr>
<td class="label">CaMKII</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">PKA</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">PKC</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">Src-family kinases</td>
<td>Tyrosine phosphorylation</td>
</tr>
<tr>
<td class="label">GRIP1</td>
<td>PDZ binding</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Memantine</td>
<td>Uncompetitive NMDA antagonist</td>
</tr>
<tr>
<td class="label">Ketamine</td>
<td>Non-competitive antagonist</td>
</tr>
<tr>
<td class="label">D-cycloserine</td>
<td>Partial agonist at glycine site</td>
</tr>
<tr>
<td class="label">Site</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">Ser896 (GluN1)</td>
<td>PKC</td>
</tr>
<tr>
<td class="label">Ser897 (GluN1)</td>
<td>PKC</td>
</tr>
<tr>
<td class="label">Tyr1325 (GluN2B)</td>
<td>Src</td>
</tr>
<tr>
<td class="label">Tyr1472 (GluN2B)</td>
<td>Src</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">33 edges</a></td>
</tr>
</table>

Overview

Glutamate Receptor Ionotropic NMDA Subunit 1 (GluN1), encoded by the GRIN1 gene, is the obligatory subunit of the N-methyl-D-aspartate (NMDA) receptor, a glutamate-gated ion channel critical for synaptic plasticity, learning, and memory. The NMDA receptor is one of three major ionotropic glutamate receptor families (along with AMPA and kainate receptors) and stands out for its unique pharmacological properties, voltage-dependent magnesium block, and high calcium permeability. These characteristics make NMDA receptors central to activity-dependent synaptic modifications that underlie learning, memory, and neural development[@traynelis2010].

The GRIN1 gene is located on chromosome 9q34.3 and undergoes extensive alternative splicing to produce multiple isoforms with distinct properties. The resulting GluN1 protein is approximately 105 kDa and contains 938 amino acids. Each functional NMDA receptor requires two GluN1 subunits combined with two GluN2 (A-D) or GluN3 (A-B) subunits. The receptor is highly expressed in the central nervous system, particularly in the hippocampus, cerebral cortex, basal ganglia, and thalamus, where it plays fundamental roles in excitatory neurotransmission and higher cognitive functions[@paoletti2013].

Structure and Architecture

Protein Domain Organization

The GluN1 subunit contains four distinct structural domains that cooperate to form functional NMDA receptor complexes:

N-terminal Domain (NTD, residues 1-380): The extracellular N-terminal domain adopts a clamshell-like structure that regulates receptor assembly, trafficking, and allosteric modulation. The NTD contains binding sites for various modulators including zinc ions and ifenprodil-like compounds. It plays critical roles in subunit assembly and determines the pharmacological properties of the assembled receptor[@hardingham2002].

Ligand-binding Domain (LBD, residues 400-560 and 620-800): The LBD is formed by two polypeptide segments (S1 and S2) that create the binding pocket for glycine or D-serine, the obligatory co-agonist required for receptor activation. The LBD undergoes dramatic conformational changes upon agonist binding, transitioning from open to closed states that translate to channel opening. Glycine binding affinity varies among splice variants, affecting receptor sensitivity to co-agonist concentrations[@liu2007].

Transmembrane Domain (TMD, residues 810-870): The TMD consists of three transmembrane helices (M1, M3, M4) and a reentrant pore loop (M2) that lines the ion channel pore. The M2 segment contains an asparagine residue (N598) that determines calcium permeability and magnesium block characteristics. The channel pore has a diameter of approximately 5-6 Å, allowing passage of small cations including sodium, potassium, and calcium[@zhou2023].

C-terminal Domain (CTD, residues 876-938): The intracellular C-terminal domain contains multiple phosphorylation sites and PDZ-domain binding motifs that anchor the receptor to scaffolding proteins including PSD-95, SAP-97, and Homer. The CTD is the primary site for regulatory modifications including phosphorylation by PKA, PKC, CaMKII, and src-family tyrosine kinases. Alternative splicing generates variants with different CTD lengths and properties[@cullcandy2010].

Subunit Assembly and Stoichiometry

Functional NMDA receptors assemble as heterotetramers:

• Typical composition: 2 × GluN1 + 2 × GluN2
• Alternative compositions: Can include GluN3 subunits to form GluN1/GluN3 or GluN1/GluN2/GluN3 receptors
• Diheteromeric vs. triheteromeric: Most receptors contain two identical GluN2 subunits (diheteromeric), though triheteromeric receptors with different GluN2 subunits exist

Normal Physiological Functions

Excitatory Synaptic Transmission

NMDA receptors mediate a significant portion of excitatory synaptic transmission in the central nervous system. Unlike AMPA receptors, NMDA receptors have several unique properties:

Voltage-dependent magnesium block: At resting membrane potentials, magnesium ions block the channel pore. Depolarization relieves this block, allowing ion flow. This property makes NMDA receptors coincidence detectors, requiring both presynaptic glutamate release and postsynaptic depolarization for activation.

High calcium permeability: Approximately 10-15% of the current is carried by calcium ions, making NMDA receptors major sources of activity-dependent calcium influx. This calcium signal triggers downstream signaling cascades involved in synaptic plasticity.

Slow kinetics: NMDA receptor currents have a slow rise and decay compared to AMPA receptors, contributing to the temporal integration of synaptic inputs and the induction of synaptic plasticity[@hansen2019].

Synaptic Plasticity

NMDA receptors are essential for both long-term potentiation (LTP) and long-term depression (LTD), the cellular substrates of learning and memory:

Long-term potentiation (LTP): Strong synaptic activation leads to substantial calcium influx through NMDA receptors, activating CaMKII and other signaling molecules that enhance synaptic strength. LTP involves phosphorylation of AMPA receptor subunits, insertion of additional AMPA receptors into the postsynaptic membrane, and structural changes in dendritic spines.

Long-term depression (LTD): Weaker synaptic activation produces modest calcium influx that activates protein phosphatases, removing AMPA receptors from the synapse. LTD is thought to be important for forgetting and synaptic refinement.

The subunit composition of NMDA receptors influences the induction threshold for LTP and LTD, with different GluN2 subunits conferring distinct plasticity properties[@wyllie2013].

Brain Development

During development, NMDA receptors play crucial roles in:

Synapse formation: Activity-dependent NMDA receptor signaling guides the formation and refinement of excitatory synapses.

Neuronal survival: Appropriate NMDA receptor activity promotes neuronal survival, while either insufficient or excessive activity can trigger cell death pathways.

Critical period plasticity: NMDA receptor-dependent plasticity is particularly prominent during critical periods of brain development, when sensory experience shapes neural circuits.

Circuit maturation: NMDA receptors help establish mature connectivity patterns in various brain regions including the visual cortex, hippocampus, and cerebellum[@petersen2018].

Role in Neurodegenerative Diseases

Alzheimer's Disease

NMDA receptor dysfunction is central to Alzheimer's disease pathogenesis:

Excitotoxicity: Excessive glutamate release or prolonged NMDA receptor activation leads to calcium overload, activating destructive enzymatic pathways including proteases, lipases, and nucleases. This excitotoxic mechanism contributes to synaptic loss and neuronal death.

Amyloid-beta effects: Aβ oligomers directly interact with NMDA receptors, particularly those containing GluN2B subunits, causing dysregulated calcium homeostasis and synaptic dysfunction. Aβ binding to NMDA receptors triggers internalization and reduces surface expression.

Tau pathology: Hyperphosphorylated tau affects NMDA receptor trafficking and function. Tau can interact with PSD-95 and other scaffolding proteins, disrupting the synaptic localization of NMDA receptors. Tau pathology also enhances NMDA receptor-mediated excitotoxicity.

Therapeutic implications: Memantine, an uncompetitive NMDA receptor antagonist, is approved for moderate-to-severe AD. It blocks overactive NMDA receptors while sparing normal synaptic transmission[@kumar2015].

Parkinson's Disease

NMDA receptors contribute to dopaminergic neuron degeneration and PD symptoms:

Excitotoxicity in substantia nigra: Dopaminergic neurons are particularly vulnerable to excitotoxic damage due to their high NMDA receptor expression and unique electrophysiological properties.

Levodopa-induced dyskinesias: Chronic levodopa treatment leads to altered NMDA receptor phosphorylation and trafficking in striatal neurons, contributing to the development of dyskinesias. NMDA receptor antagonists including amantadine reduce dyskinesias.

Basal ganglia dysfunction: NMDA receptor-mediated changes in striatal output contribute to the motor symptoms of PD including bradykinesia and rigidity.

Neuroprotection strategies: NMDA receptor modulation represents a potential neuroprotective strategy, though systemic blockade causes unacceptable side effects[@li2021].

Stroke and Ischemia

NMDA receptors mediate excitotoxic cell death in stroke:

Massive glutamate release: Ischemia triggers excessive glutamate release from neurons and astrocytes.

Calcium overload: The resulting overactivation of NMDA receptors causes catastrophic calcium influx.

Excitotoxic cascade: Elevated calcium activates destructive enzymatic pathways, leading to rapid neuronal death in the ischemic penumbra.

Therapeutic failure: Despite clear mechanistic involvement, NMDA receptor antagonists have failed in clinical stroke trials due to unacceptable side effects and narrow therapeutic windows.

Amyotrophic Lateral Sclerosis

Motor neurons are particularly vulnerable to NMDA receptor-mediated excitotoxicity:

Elevated expression: Motor neurons express high levels of NMDA receptors, increasing their susceptibility to excitotoxic damage.

Glutamate transport defects: Reduced glutamate transport in ALS leads to elevated extracellular glutamate levels.

Therapeutic approaches: Memantine and other NMDA antagonists have been tested in ALS, though with limited success.

Interaction Network

Protein-Protein Interactions

Signaling Pathways

• CaMKII activation: Calcium influx activates CaMKII, which phosphorylates AMPA receptors and increases synaptic strength
• MAPK/ERK pathway: Activity-dependent gene transcription required for LTP maintenance
• CREB activation: Calcium-dependent gene expression
• Calcineurin: Calcium-activated phosphatase that triggers LTD

Therapeutic Approaches

Approved Drugs

Experimental Approaches

Subunit-selective modulators: Targeting GluN2A or GluN2B-containing receptors specifically may reduce side effects.

Allosteric modulators: Positive allosteric modulators that enhance receptor function without causing global excitation.

Glycine site modulators: Targeting the glycine binding site offers alternative modulation strategies.

Activity-dependent blockade: Developing drugs that preferentially block pathologically active receptors while sparing normal function.

Challenges

• Narrow therapeutic window: NMDA blockade causes psychosis, cognitive impairment, and other side effects
• Circuit-specific effects: Global NMDA modulation affects both protective and destructive pathways
• Developmental concerns: NMDA receptor blockade during development can cause irreversible deficits

Alternative Splicing

The GRIN1 gene produces multiple splice variants with distinct properties:

Major Splice Variants

• GluN1-1a: Full-length isoform, most common
• GluN1-1b: Alternative C-terminus
• GluN1-2a/b: Exon 21 inclusion/exclusion
• GluN1-3a/b: Exon 22 inclusion/exclusion
• GluN1-4a/b: C-terminal variations

Functional Consequences

Splice variants differ in:

• Glycine sensitivity
• Agonist potency
• Channel kinetics
• Trafficking properties
• Phosphorylation sites

Post-Translational Modifications

Phosphorylation

Multiple sites regulate NMDA receptor function:

Other Modifications

• Palmitoylation: Regulates membrane association
• Glycosylation: Affects assembly and trafficking
• Ubiquitination: Targets receptors for degradation

Animal Models

Knockout Studies

• GluN1 knockout: Embryonic lethal, severe neuronal deficits
• Conditional knockouts: Region-specific deletion reveals specific functions

Transgenic Models

• GluN2B overexpression: Enhanced LTP, learning deficits in some models
• Mutant mice: Point mutations to study specific channel properties
• Disease models: APP/PS1, MPTP, and other neurodegenerative models

See Also

• [GRIN1 Gene](/genes/grin1)
• [NMDA Receptors](/entities/nmda-receptor)
• [Glutamate Signaling](/entities/glutamate-receptors)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Excitotoxicity](/mechanisms/excitotoxicity)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)

External Links

• [UniProt: P35439](https://www.uniprot.org/uniprot/P35439)
• [PDB: 5U8C](https://www.rcsb.org/structure/5U8C)
• [IUPHAR: NMDA Receptors](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456)

References